Skip to main content
. 2013 Feb 26;15(1):R15. doi: 10.1186/bcr3390

Table 4.

Odds ratios and 95% confidence intervals for breast cancer risk according to pre-specified categories of circulating 25(OH)D concentration by seasona

Pre-specified categories, nmol/L Continuousb P value

< 50 50-74 75+ P trend
Winter (Jan., Feb., March, April)

Both cohortsc Cases/controls 391/704 244/472 65/116
OR (95% CI) 1.0 (ref) 0.94 (0.77, 1.15) 1.06 (0.76, 1.48) 0.95 0.97 (0.82, 1.15) 0.74

NYUWHS Cases/controls 193/331 105/217 35/65
OR (95% CI) 1.0 (ref) 0.82 (0.61, 1.10) 0.91 (0.58, 1.44) 0.35 0.90 (0.73, 1.13) 0.37

NSMSC Cases/controls 198/373 139/255 30/51
OR (95% CI) 1.0 (ref) 1.10 (0.83, 1.46) 1.25 (0.76, 2.06) 0.34 1.11 (0.85, 1.47) 0.44

Summer (July, Aug., Sept.)

Both cohortsc Cases/controls 113/186 217/348 99/212
OR (95% CI) 1.0 (ref) 1.02 (0.75, 1.38) 0.76 (0.53, 1.09) 0.14 0.82 (0.64, 1.05) 0.12

NYUWHS Cases/controls 77/121 125/190 67/148
OR (95% CI) 1.0 (ref) 1.07 (0.73, 1.56) 0.69 (0.45, 1.07) 0.10 0.80 (0.60, 1.07) 0.14

NSMSC Cases/controls 36/65 92/158 32/64
R (95% CI) 1.0 (ref) 0.99 (0.59, 1.67) 0.89 (0.46, 1.70) 0.72 0.88 (0.52, 1.47) 0.61

aAdjusted for age at menarche (continuous), family history of breast cancer (no or yes), age at first birth/parity (≤ 20, 21-25, 26-30, > 30 years, nulliparous), body mass index (continuous), hormone replacement therapy use (never or ever), and alcohol consumption (continuous). bOdds ratio (OR) for a doubling in 25(OH)D level. cAdjusted for cohort in addition to all factors in footnote a. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; NSMSC, Northern Sweden Mammary Screening Cohort; NYUWHS, New York University Women's Health Study; ref, reference.